LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program.Inflamm Bowel Dis已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other。 | PMID 40184206PMC12455601 | 2025-Sep-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Radiation Therapy Dose Escalation Failed to Improve Local Control for Intermediate-Risk Rhabdomyosarcoma on ARST1431: A Report From the Children's Oncology Group.Int J Radiat Oncol Biol PhysKM panel re-extraction failed | PMID 40185209PMC12353335 | 2025-Sep-01 | 0.85 | The study is a randomized phase III trial in human oncology reporting original results, but it evaluates a radiation therapy dose escalation strategy and does not involve a drug-containing intervention. The primary endpoint is local failure, reported as a percentage rate at a fixed time point, not a time-to-event analysis with Kaplan-Meier curves or hazard ratios. Therefore, it does not meet the inclusion criteria for a drug intervention and a primary/key secondary time-to-event efficacy endpoint. | 无 KM 图 |
| Outcomes in Systemic Sclerosis-Associated Interstitial Lung Disease Based on Serological Profiles With a Focus on Anticentromere and Anti-RNA Polymerase III Antibodies.J RheumatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40233987无 PMCID | 2025-Sep-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Clinically Inactive Disease and Remission in Patients With Juvenile Idiopathic Arthritis Receiving Tofacitinib: Post Hoc Analysis of a Phase III Trial.J RheumatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40312101无 PMCID | 2025-Sep-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Optimal Head-of-Bed Positioning Before Thrombectomy in Large Vessel Occlusion Stroke: A Randomized Clinical Trial.JAMA Neurol | PMID 40465238PMC12138796 | 2025-Sep-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial.Diabetes Care已检查 3 张 PubMed Figure,均未识别为 KM 图:captionless-figure:AI 判定为 forest plot;Figure 1:森林图/亚组分析图;Figure 2:森林图/亚组分析图。 | PMID 40543068PMC12368379 | 2025-Sep-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical Trial.JAMA Dermatol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1.:研究设计图;Figure 2.:AI 判定为 other;Figure 3.:AI 判定为 other。 | PMID 40560554PMC12199185 | 2025-Sep-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones: Cohort A of the VISIBLE Randomized Clinical Trial.JAMA Dermatol已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:研究设计图;Figure 2:AI 判定为 multi panel km;Figure 3:AI 判定为 multi panel km。 | PMID 40560559PMC12199184 | 2025-Sep-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of sacubitril/valsartan in Afro-descendant patients with resistant hypertension: a randomized controlled trial.J HypertensPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40621831无 PMCID | 2025-Sep-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Behavioral Compared With Drug Therapy for Overactive Bladder Symptoms in Parkinson Disease: A Randomized Noninferiority Trial.JAMA NeurolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40658410PMC12261112 | 2025-Sep-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial.Diabetes Care已检查 4 张 PubMed Figure,均未识别为 KM 图:captionless-figure:AI 判定为 other;Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other。 | PMID 40694530PMC12368374 | 2025-Sep-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Tibremciclib or Placebo Plus Fulvestrant in Hormone Receptor-Positive and ERBB2-Negative Advanced Breast Cancer After Endocrine Therapy: A Randomized Clinical Trial.JAMA Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1.:CONSORT/入组流程图;Figure 2.:森林图/亚组分析图。 | PMID 40742733PMC12314770 | 2025-Sep-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer.Cancer Res CommunAI 判定该论文不进入自动 KM 提取:This is a retrospective validation study of a diagnostic test using samples from a prior phase III trial, not a report of a new phase III randomized controlled clinical trial. | PMID 40832988PMC12417970 | 2025-Sep-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Impact of temporary atezolizumab and bevacizumab interruption on survival in advanced HCC: an IMbrave150 analysis.Oncologist入排复审未纳入:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | PMID 40891895PMC12475964 | 2025-Sep-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancer.Endocr Relat Cancer已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图。 | PMID 40888443PMC12433830 | 2025-Sep-01 | 0.85 | The study is a Phase III randomized trial in oncology with a drug intervention, but its primary endpoints are pathological response scores (PEPI, EPclin), not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Therefore, it does not meet the core requirement for Kaplan-Meier digitization. | 无 KM 图 |
| Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial.PLoS Med入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40972137PMC12459851 | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion: 72-Week Results from the BALATON and COMINO Trials.Ophthalmol RetinaPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40107501无 PMCID | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study.J Hepatol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40154623无 PMCID | 2025-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Endoscopic balloon dilation with steroid injection versus radial incision and cutting with steroid injection for refractory esophageal anastomotic stricture: a randomized study.Endoscopy入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40199498无 PMCID | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of low-dose atorvastatin plus ezetimibe for primary hypercholesterolemia: A randomized, double-blind, multicenter phase 3 trial.Lipids已检查 4 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:CONSORT/入组流程图;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other。 | PMID 40251695PMC12434550 | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Influence of anticoagulant concomitant medication on wound healing: Analysis of a multicentre cohort of 212 patients with a uniform wound model.Br J Clin Pharmacol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40289279无 PMCID | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Endothelial Glycocalyx Degradation in Sepsis: Analysis of the Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis (CLOVERS) Trial, a Multicenter, Phase 3, Randomized Trial.Ann Am Thorac SocPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40315385PMC12416157 | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of relugolix combination therapy in women with uterine fibroids and adenomyosis: subgroup analysis of LIBERTY 1 and LIBERTY 2.Fertil Steril入排复审未纳入:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | PMID 40320117无 PMCID | 2025-Sep | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Laryngeal Reinnervation vs Type I Thyroplasty in Unilateral Vocal Fold Paralysis (VOCALIST): A Randomized Feasibility Study.Laryngoscope入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40323143PMC12371777 | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Switching Patients With Congenital Adrenal Hyperplasia to Modified-Release Hydrocortisone Capsules: Relative Bioavailability and Disease Control.Clin Endocrinol (Oxf)已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:ROC 图;Figure 2:ROC 图。 | PMID 40377230PMC12319290 | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3, a phase 3, randomized double-blind study.J Am Acad DermatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40378883无 PMCID | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitis.J Am Acad Dermatol入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40383273无 PMCID | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304).Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40403846无 PMCID | 2025-Sep | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study.J Thorac Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40419140无 PMCID | 2025-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Twenty-year survival of advanced gastrointestinal stromal tumours treated with imatinib: exploratory long-term follow-up of the BFR14 trial.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40447230无 PMCID | 2025-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Visual Acuity and Quality of Life Outcomes With Pegcetacoplan Treatment: A Post Hoc Analysis From the OAKS and DERBY Trials.Am J OphthalmolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40449644无 PMCID | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40450503无 PMCID | 2025-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Lidocaine for Neuropathic Cancer Pain (LiCPain): A Pilot Randomized Controlled Trial.J Pain Symptom Manage入排复审未纳入:The study is a randomized, double-blind, placebo-controlled trial in humans with cancer pain, involving a drug intervention (lidocaine). However, it is a pilot/feasibility study (not a definitive Phase III/IIIb or Phase II/III trial), and its primary endpoint is pain intensity reduction, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). Therefore, it does not meet the eligibility criteria. | PMID 40466924无 PMCID | 2025-Sep | 0.90 | The study is a randomized, double-blind, placebo-controlled trial in humans with cancer pain, involving a drug intervention (lidocaine). However, it is a pilot/feasibility study (not a definitive Phase III/IIIb or Phase II/III trial), and its primary endpoint is pain intensity reduction, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). Therefore, it does not meet the eligibility criteria. | 无 KM 图 |
| Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study MT-1186-A02).Muscle Nerve疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:非 KM 图;FIGURE 3:研究设计图。 | PMID 40474686PMC12338024 | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40500687无 PMCID | 2025-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Repairing Myelin After Irradiated Pediatric Brain Tumor: A Magnetization Transfer Imaging Analysis.Pediatr Blood Cancer入排复审未纳入:The study is a randomized Phase III trial in pediatric brain tumor survivors comparing exercise and metformin interventions. However, its primary/secondary endpoints are neuroimaging changes (MTR, FA) and cognitive outcomes, not a time-to-event efficacy endpoint (like OS, PFS) as required. Therefore, it is not eligible for the Kaplan-Meier digitization cohort. | PMID 40515500无 PMCID | 2025-Sep | 0.95 | The study is a randomized Phase III trial in pediatric brain tumor survivors comparing exercise and metformin interventions. However, its primary/secondary endpoints are neuroimaging changes (MTR, FA) and cognitive outcomes, not a time-to-event efficacy endpoint (like OS, PFS) as required. Therefore, it is not eligible for the Kaplan-Meier digitization cohort. | 无 KM 图 |
| Evaluation of the Childhood Hodgkin International Prognostic Score (CHIPS) in High-Risk Pediatric Hodgkin Lymphoma Patients Treated on Children's Oncology Group AHOD1331.Pediatr Blood Cancer | PMID 40515508PMC12230980 | 2025-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Psychometric analysis of the Neuro-QoL Fatigue in generalized Myasthenia Gravis (gMG) using data from a phase 3 trial.Qual Life ResPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40515798无 PMCID | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A Restrictive Versus a Liberal Transfusion Strategy in Patients With Spontaneous Intracerebral Hemorrhage: A Secondary Analysis of TRAIN Randomized Clinical Trial.Stroke疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1.:非 KM 图;Figure 2.:非 KM 图。 | PMID 40525290PMC12372721 | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.Diabetes Obes Metab入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40537987PMC12326929 | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: A double-blind, randomized controlled trial.Headache已检查 1 张 PMC Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram。 | PMID 40542538PMC12455392 | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Pembrolizumab in relapsed or refractory Hodgkin lymphoma: a post hoc analysis of KEYNOTE-204 by prior lines of therapy.Leuk Lymphoma疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40548833无 PMCID | 2025-Sep | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Diabetes EndocrinolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40555243无 PMCID | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Guselkumab in East Asians With Moderate-to-Severe Ulcerative Colitis: Subgroup Analysis of the QUASAR Induction and Maintenance Studies.J Gastroenterol Hepatol | PMID 40574492PMC12400247 | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Hypokalemia During Decongestion With Loop Diuretics and Hydrochlorothiazide, a Post Hoc Analysis of the CLOROTIC Trial.Circ Heart Fail入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40590131无 PMCID | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Survival Outcomes with Cilta-cel Versus Conventional Treatment Regimens for Patients with Lenalidomide-Refractory Multiple Myeloma Using Inverse Probability of Treatment Weighting.Adv TherAI 判定该论文不进入自动 KM 提取:This is an indirect comparison (meta-analysis-like) using pooled individual patient data from multiple prior trials (CARTITUDE-4, CASTOR, CANDOR, APOLLO) via statistical adjustment (IPTW), not a direct report of a single human Phase III randomized controlled trial. | PMID 40613875PMC12394250 | 2025-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Predicting acute diarrhoea in rectal cancer chemoradiotherapy: Secondary analysis of the phase III ARISTOTLE trial.Radiother OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40618901无 PMCID | 2025-Sep | 0.80 | The study is a secondary analysis of a definitive phase III randomized oncology trial, but it reports on predicting a toxicity endpoint (acute diarrhoea) rather than a survival, progression, recurrence, death, or time-to-event efficacy outcome, making it ineligible for the current cohort. | 无 KM 图 |
| Concordance of molecular microbiology and conventional culture techniques for infected diabetic foot ulcer management.Diabet Med入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40634121PMC12352717 | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Intraoperative corticosteroid administration for resectable gastric cancer: a multicenter, randomized, open-label, phase II/III study.Gastric Cancer | PMID 40638018PMC12378285 | 2025-Sep | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis Treated with Stapokibart over 52 weeks: A Post Hoc Analysis of a Phase 3 Trial.Adv TherPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40650707无 PMCID | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |